Compare Stocks: AMRN, SPTX, AMPH, and PCRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$26.13	$21.87	$16.65 ▼ $29.52	$1.11B	0.92	498,454 shs	370,895 shs
AMRN Amarin	$13.20	$13.95	$12.96 ▼ $20.90	$278.78M	0.76	51,120 shs	127,281 shs
PCRX Pacira BioSciences	$25.12	$25.32	$18.80 ▼ $27.66	$1.00B	0.26	524,190 shs	439,930 shs
SPTX Seaport Therapeutics	$21.52	$22.87	$14.85 ▼ $28.38	$1.15B	N/A	256,833 shs	192,796 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	0.00%	+10.63%	+18.72%	+26.17%	-2.68%
AMRN Amarin	0.00%	-3.15%	-5.51%	-17.09%	-17.50%
PCRX Pacira BioSciences	0.00%	+1.74%	-2.48%	+0.12%	-0.48%
SPTX Seaport Therapeutics	0.00%	+0.61%	-10.48%	-4.44%	+2,151,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$26.13	$21.87	$16.65 ▼ $29.52	$1.11B	0.92	498,454 shs	370,895 shs
AMRN Amarin	$13.20	$13.95	$12.96 ▼ $20.90	$278.78M	0.76	51,120 shs	127,281 shs
PCRX Pacira BioSciences	$25.12	$25.32	$18.80 ▼ $27.66	$1.00B	0.26	524,190 shs	439,930 shs
SPTX Seaport Therapeutics	$21.52	$22.87	$14.85 ▼ $28.38	$1.15B	N/A	256,833 shs	192,796 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	0.00%	+10.63%	+18.72%	+26.17%	-2.68%
AMRN Amarin	0.00%	-3.15%	-5.51%	-17.09%	-17.50%
PCRX Pacira BioSciences	0.00%	+1.74%	-2.48%	+0.12%	-0.48%
SPTX Seaport Therapeutics	0.00%	+0.61%	-10.48%	-4.44%	+2,151,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMPH Amphastar Pharmaceuticals	1.75	Reduce	$22.50	-13.89% Downside
AMRN Amarin	1.33	Sell	$13.00	-1.52% Downside
PCRX Pacira BioSciences	2.33	Hold	$30.14	20.00% Upside
SPTX Seaport Therapeutics	2.50	Moderate Buy	$38.57	79.24% Upside

Current Analyst Ratings Breakdown

Latest AMRN, SPTX, AMPH, and PCRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/25/2026	SPTX Seaport Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Strong-Buy	$46.00
9/25/2026	SPTX Seaport Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/23/2026	PCRX Pacira BioSciences	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$32.00
9/16/2026	PCRX Pacira BioSciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D+)
9/10/2026	SPTX Seaport Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$50.00
9/9/2026	PCRX Pacira BioSciences	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform	$28.00
9/1/2026	PCRX Pacira BioSciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
8/26/2026	SPTX Seaport Therapeutics	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$32.00
8/21/2026	AMRN Amarin	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Underweight	$13.00
8/20/2026	SPTX Seaport Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$50.00
8/18/2026	AMPH Amphastar Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$20.00 ➝ $23.00

(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMPH Amphastar Pharmaceuticals	$719.89M	1.54	$4.26 per share	6.14	$17.17 per share	1.52
AMRN Amarin	$213.65M	1.30	$0.36 per share	36.57	$22.07 per share	0.60
PCRX Pacira BioSciences	$726.41M	1.38	$3.86 per share	6.51	$16.11 per share	1.56
SPTX Seaport Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMPH Amphastar Pharmaceuticals	$98.09M	$1.69	15.46	10.09	5.03	10.76%	14.98%	6.96%	11/5/2026 (Estimated)
AMRN Amarin	-$38.80M	-$0.99	N/A	N/A	N/A	-14.56%	-0.20%	-0.14%	11/4/2026 (Estimated)
PCRX Pacira BioSciences	$7.03M	$0.35	71.77	10.05	N/A	1.96%	9.68%	5.30%	11/5/2026 (Estimated)
SPTX Seaport Therapeutics	-$74.88M	-$12.12	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest AMRN, SPTX, AMPH, and PCRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	AMPH Amphastar Pharmaceuticals	$0.62	$0.91	+$0.29	$0.67	$179.92 million	$183.90 million
8/4/2026	Q2 2026	PCRX Pacira BioSciences	$0.6460	$0.73	+$0.0840	$0.12	$191.06 million	$192.40 million
8/3/2026	Q2 2026	SPTX Seaport Therapeutics	-$0.71	-$1.78	-$1.07	-$1.78	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AMRN Amarin	N/A	N/A	N/A	N/A	N/A
PCRX Pacira BioSciences	N/A	N/A	N/A	N/A	N/A
SPTX Seaport Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMPH Amphastar Pharmaceuticals	0.79	2.40	1.71
AMRN Amarin	N/A	3.67	2.67
PCRX Pacira BioSciences	0.54	5.04	3.94
SPTX Seaport Therapeutics	N/A	18.00	18.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMPH Amphastar Pharmaceuticals	65.09%
AMRN Amarin	22.25%
PCRX Pacira BioSciences	99.73%
SPTX Seaport Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
AMPH Amphastar Pharmaceuticals	29.60%
AMRN Amarin	4.21%
PCRX Pacira BioSciences	6.40%
SPTX Seaport Therapeutics	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMPH Amphastar Pharmaceuticals	1,976	42.54 million	29.95 million	Optionable
AMRN Amarin	80	21.12 million	20.23 million	Optionable
PCRX Pacira BioSciences	829	39.86 million	37.31 million	Optionable
SPTX Seaport Therapeutics	58	53.53 million	N/A	N/A

AMRN, SPTX, AMPH, and PCRX Headlines

Recent News About These Companies

Seaport Therapeutics (NASDAQ:SPTX) Upgraded at Raymond James Financial

2 hours ago | americanbankingnews.com

Seaport Therapeutics, Inc. $SPTX Shares Newly Acquired by State Street Corp

September 27 at 3:28 AM | marketbeat.com

Seaport Therapeutics, Inc. : Raymond James réitère son opinion positive sur le titre

September 26 at 8:20 AM | zonebourse.comZ

Raymond James initiates coverage of Seaport Therapeutics at strong buy

September 26 at 8:20 AM | msn.com

Seaport Therapeutics (NASDAQ:SPTX) Stock Lifted to "Strong-Buy" by Raymond James Financial

September 26 at 6:29 AM | marketbeat.com

Seaport Therapeutics (NASDAQ:SPTX) Shares Gap Up - Here's Why

September 25 at 10:59 AM | marketbeat.com

Seaport Therapeutics (NASDAQ:SPTX) Shares Gap Up - Here's What Happened

September 15, 2026 | marketbeat.com

Seaport Therapeutics to Participate in September Investor Conferences

September 14, 2026 | finance.yahoo.com

Seaport Therapeutics to Participate in September Investor Conferences

September 14, 2026 | businesswire.com

The Manufacturers Life Insurance Company Acquires New Stake in Seaport Therapeutics, Inc. $SPTX

September 14, 2026 | marketbeat.com

Seaport Therapeutics (NASDAQ:SPTX) Stock Price Up 4.6% - Should You Buy?

September 10, 2026 | marketbeat.com

HC Wainwright Reaffirms Buy Rating for Seaport Therapeutics (NASDAQ:SPTX)

September 10, 2026 | marketbeat.com

Seaport Therapeutics Says GlyphAllo Shows no Next-Morning Driving Impairment in Phase 1 Trial

September 9, 2026 | finance.yahoo.com

Seaport Therapeutics Reports Positive Topline Results From Phase 1 Driving Simulation Trial Of GlyphAllo In Healthy Volunteers

September 9, 2026 | marketscreener.comM

Seaport Reports Positive GlyphAllo Driving Trial Results In Healthy Volunteers

September 9, 2026 | rttnews.com

PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers

September 9, 2026 | businesswire.com

Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers

September 9, 2026 | finance.yahoo.com

Citadel Advisors LLC Takes Position in Seaport Therapeutics, Inc. $SPTX

September 8, 2026 | marketbeat.com

Braidwell LP Takes $10.86 Million Position in Seaport Therapeutics, Inc. $SPTX

September 3, 2026 | marketbeat.com

Seaport Therapeutics, Inc. (NASDAQ:SPTX) Given Consensus Rating of "Hold" by Analysts

September 3, 2026 | marketbeat.com

Alyeska Investment Group L.P. Makes New $1.63 Million Investment in Seaport Therapeutics, Inc. $SPTX

September 2, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMRN, SPTX, AMPH, and PCRX Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

$26.13 0.00 (0.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$26.13 0.00 (0.00%)

As of 09/25/2026 07:30 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Amarin NASDAQ:AMRN

$13.20 0.00 (0.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$13.20 0.00 (-0.04%)

As of 09/25/2026 07:30 PM Eastern

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Pacira BioSciences NASDAQ:PCRX

$25.12 0.00 (0.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$25.11 -0.01 (-0.04%)

As of 09/25/2026 07:30 PM Eastern

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Seaport Therapeutics NASDAQ:SPTX

$21.52 0.00 (0.00%)

As of 09/25/2026 04:00 PM Eastern

Seaport Therapeutics Inc. is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety and other debilitating neuropsychiatric disorders. Seaport Therapeutics Inc. is based in BOSTON.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AMRN, SPTX, AMPH, and PCRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AMRN, SPTX, AMPH, and PCRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AMRN, SPTX, AMPH, and PCRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMRN, SPTX, AMPH, and PCRX Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

Amarin NASDAQ:AMRN

Pacira BioSciences NASDAQ:PCRX

Seaport Therapeutics NASDAQ:SPTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AMRN, SPTX, AMPH, and PCRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AMRN, SPTX, AMPH, and PCRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AMRN, SPTX, AMPH, and PCRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMRN, SPTX, AMPH, and PCRX Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

Amarin NASDAQ:AMRN

Pacira BioSciences NASDAQ:PCRX

Seaport Therapeutics NASDAQ:SPTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools